Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Ketterer

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2011
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remissionFranz Buchegger, Cristian Antonescu, Claudine Helg, et al.
Bulletin Du Cancer|August 27, 2005
Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literatureAnne-Claude George, Mahmut Ozsahin, Robert Janzer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 9, 2011
Home care--a safe and attractive alternative to inpatient administration of intensive chemotherapiesFrançois Lüthi, Nadia Fucina, Nathalie Divorne, et al.
Leukemia & Lymphoma|April 15, 2003
HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration studyGiannicola D'Addario, Alexander Dieterle, Joachim Torhorst, et al.
Swiss Medical Weekly|August 5, 2011
Diagnosis and treatment of follicular lymphomaFelicitas Hitz, Nicolas Ketterer, Andreas Lohri, et al.
Clinical Nuclear Medicine|September 8, 2012
Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better toleranceFranz Buchegger, John O Prior, Gilles Allenbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2005
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kineticsCristian Antonescu, Angelika Bischof Delaloye, Marek Kosinski, et al.
British Journal of Haematology|March 6, 2010
Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective studyBiju Krishnan, Monica Else, Geir E Tjonnfjord, et al.
Hematological Oncology|September 29, 2016
Y<sup>90</sup> -Ibritumomab tiuxetan (Y<sup>90</sup> -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)Michèle Voegeli, Stephanie Rondeau, Simona Berardi Vilei, et al.
International Journal of Radiation Oncology, Biology, Physics|February 19, 2002
Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network studyAbderrahim Zouhair, Damien Weber, Yazid Belkacémi, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2011
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remissionFranz Buchegger, Cristian Antonescu, Claudine Helg, et al.
Bulletin Du Cancer|August 27, 2005
Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literatureAnne-Claude George, Mahmut Ozsahin, Robert Janzer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 9, 2011
Home care--a safe and attractive alternative to inpatient administration of intensive chemotherapiesFrançois Lüthi, Nadia Fucina, Nathalie Divorne, et al.
Leukemia & Lymphoma|April 15, 2003
HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration studyGiannicola D'Addario, Alexander Dieterle, Joachim Torhorst, et al.
Swiss Medical Weekly|August 5, 2011
Diagnosis and treatment of follicular lymphomaFelicitas Hitz, Nicolas Ketterer, Andreas Lohri, et al.
Clinical Nuclear Medicine|September 8, 2012
Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better toleranceFranz Buchegger, John O Prior, Gilles Allenbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2005
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kineticsCristian Antonescu, Angelika Bischof Delaloye, Marek Kosinski, et al.
British Journal of Haematology|March 6, 2010
Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective studyBiju Krishnan, Monica Else, Geir E Tjonnfjord, et al.
Hematological Oncology|September 29, 2016
Y<sup>90</sup> -Ibritumomab tiuxetan (Y<sup>90</sup> -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)Michèle Voegeli, Stephanie Rondeau, Simona Berardi Vilei, et al.
International Journal of Radiation Oncology, Biology, Physics|February 19, 2002
Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network studyAbderrahim Zouhair, Damien Weber, Yazid Belkacémi, et al.
Pageof 5